Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Novel agents in CLL: acalabrutinib and zanubrutinib

Barbara Eichhorst • 16 Jun 2019
EHA 2019
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Ibrutinib Zanubrutinib
ALPINE ASCEND

Barbara Eichhorst, MD, from the University Hospital of Cologne, Cologne, Germany, discusses the data so far for acalabrutinib and zanubrutinib, novel BTK inhibitors for chronic lympocytic leukemia (CLL). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Barbara Eichhorst

1:05
Risk-factors for Richter’s transformation
Barbara Eichhorst • 10 Dec 2023
2:01
Updated follow-up results of the Phase III GAIA/CLL13 trial
Barbara Eichhorst • 10 Dec 2023
2:08
CLL-RT1 trial: primary endpoint analysis of tislelizumab plus zanubrutinib in patients with RT
Barbara Eichhorst • 10 Dec 2023
1:14
Current trials of interest in CLL
Barbara Eichhorst • 7 Oct 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals